Articles about Biotechnology, Pharmaceutical and Healthcare

12:45 EDT 21st March 2018 | BioPortfolio

Latest Articles on life science, biotechnology, pharmaceutical and healthcare topics and current issues.

Showing News Articles 1–25 of 38,000+

Wednesday 21st March 2018

George Mackie

bmj;360/mar21_23/k1297/FAF1faGeorge Mackie was consultant radiologist in Wolverhampton from 1971 to 2009. His career was one of innovation in a district general hospital, large volume high quality...

Yasmeen Moin

bmj;360/mar21_25/k1306/FAF1faYasmeen Moin (“Yaz”) was born to Mohammed Abdul and Tabassum Moin, both doctors. Growing up in Nuneaton, she attended King Henry VIII School in Coventry. She had a close...

Alina Teresa Piesowicz

bmj;360/mar21_26/k1307/FAF1faAlina Teresa Piesowicz was born in Warsaw in 1935. She spent her childhood in Poland during the war years before coming to England as a refugee shortly after the war...

Data deadlines loom large for the NHS

To say patient data is a contentious topic is putting it mildly. On 15 January Public Health England (PHE) faced a barrage of media disapproval for releasing data on nearly 180 000 patients with lung...

Exercise and the older brain: Trump should walk rather than take the buggy on the golf course

Although President Donald Trump does not seem to have any cognitive deficits,1 he should be made aware of the brain’s susceptibility to neurodegeneration and decline in cognitive function with age....

What I wish I’d known before my hospital discharge

If I’d had my heart attack in the 1950s, I would have stayed in the hospital for a month. Today, heart attack survivors can be back home in 3-5 days.Going homeI couldn’t wait to go home, to sleep in...

Benefits and harms in drug trials . . . and other stories

The rule of threeRandomised trials of new drugs are designed to detect benefits, and they’re always underpowered to detect adverse events. One consequence is that the balance of benefit and harm...

David John Dickson

bmj;360/mar21_18/k1304/FAF1faDavid John Dickson (“John”) was born in Nunthorpe on the outskirts of Middlesbrough, Teesside, the second of four children. His father was a surgeon born in Fife and his...

Christopher Thomas Blaiklock

bmj;360/mar21_19/k1294/FAF1faChristopher Thomas Blaiklock (“Chris”) intended to be a physician and passed the MRCP before changing his mind and training as a surgeon. He was a registrar in...

Abortion rates are similar in countries where procedure is legal or restricted

Abortion rates have declined globally over the past 25 years according to a comprehensive new report, although most of the change has occurred in developed regions with no significant change...

Protenus February Breach Report: Number of Incidents Remain Steady

The number of healthcare data breach incidents continues to remain steady, and in February’s Breach Barometer report from Protenus, it was revealed that last month, a ransomware attack was responsible for the largest single incident.

UK’s pharma and biotech support new Health and Social Care Committee report into Brexit

The associations representing the UK’s pharma and biotech industries have announced their support of the recently published findings of the new Health and Social Care Committee report into Brexit.

Graduate nurses boost post-surgical outcomes for dementia

Having more nursing staff educated to degree level providing treatment is linked to better outcomes in surgical patients with dementia, according to US researchers.

Regular FDG PET/CT Imaging Identifies Good Outcomes Among Young Osteosarcoma Patients

Imaging with FDG PET/CT may identify children and young adult osteosarcoma patients who may experience good outcomes.

Pacritinib May Benefit Patients with Myelofibrosis and Thrombocytopenia

A recent phase III study revealed a benefit with pacritinib for patients with myelofibrosis and thrombocytopenia who have experienced treatment failure with previous therapies.

MHRA grants positive opinion for volanesorsen under EAMS

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a positive opinion to Akcea Therapeutics’ volanesorsen for the treatment of familial chylomicronaemia syndrome (FCS) under the Early Access to Medicines Scheme (EAMS).

Find the Right People to Help You Succeed

Keep a mental list of people who can help you, and then strive to be the go-to person for everyone else.

Enzalutamide Granted Priority Review for Expanded Use in Prostate Cancer

The FDA is granting Priority Review for the expanded use of enzalutamide in nonmetastatic castration-resistant prostate cancer.

New Instruments, New Ideas

Let’s head off to the outer limits of current imaging technology. Two recent papers do exactly that, and I’m going to propose combining them for even more instrumental craziness. The first covers a class of cellular structure that I had no idea even existed, even though it’s been studied for many years: bacterial gas vesicles.

STAT Plus: Pharmalittle: CVS taps an Eli Lilly exec to run its PBM; Glaxo pharma chief cuts his budget

China Premier Li Keqiang plans to eliminate import taxes on cancer drugs and significantly lower those for other medicines.

Favorable Safety Profile of Pradaxa (dabigatran etexilate) Confirmed in Real-world Analysis

NewsNew data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018. The registry examined two-year safety and effectiveness outcomes of nearly 5,000 AF patients treated with dabigatran (marketed as Pradaxa).

Phase III Study Showed Roche’s TECENTRIQ (atezolizumab) Plus Chemo Reduced Risk of Worsening or Death for Patients with Advanced Squamous Lung Cancer

NewsRoche announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death compared with chemotherapy alone in the initial (first-line) treatment of people with ...

FDA Expands Approval of Adcetris for Stage III or IV Hodgkin Lymphoma in Combo with Chemotherapy

NewsThe U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.

STAT Plus: A doctor speaks, a biotech stock tanks. What happened at this invite-only health care investor conference?

A doctor speaks, a biotech stock tanks. What happened at this invite-only health care investor conference?

Viewpoints: Can Congress Make A Deal, Prop Up Obamacare?; Trump’s Speech On Opioid Plans Hit New Lows

Editorial pages highlight these health topics and others.

Quick Search